Smart Library

Investigational use for cervical radiculopathy; no verifiable published trial specific to this indication.

Investigational use; the only clinical evidence is a 7-patient case series and a 26-patient non-randomized pilot, and the proposed mechanism is hypothetical.

Investigational use for stable-phase Peyronie's disease; evidence limited to one uncontrolled Russian series of 29 patients. Standard treatments (verapamil, collagenase, surgery) remain first-line.

Investigational adjunct for peripheral vertigo persisting after Epley maneuvers or during prolonged vestibular neuritis recovery; no study specific to these conditions was identified.

Investigational use for posterior tibial nerve entrapment at the medial ankle; no clinical study of leech therapy for it was identified.

Investigational use for non-pregnancy pubic symphysis dysfunction, including osteitis pubis; no clinical study of leech therapy was identified.

Investigational adjunct for chronic tension-type headache (≥15 days/month) with persistent pericranial muscle tenderness; no study in patients diagnosed with this condition was identified.

Investigational adjunct for cervicogenic headache referred from upper cervical (C1-C3) joints; no clinical study in diagnosed cases was identified.

Investigational idea for chronic anal fissure refractory to medical therapy; no clinical study identified; sphincterotomy remains the gold standard.

Investigational adjunct for MS-related fatigue; no clinical study was identified; disease-modifying therapy and modafinil/amantadine remain primary.

Investigational adjunct for convalescent-phase Ramsay Hunt syndrome residual facial weakness; antiviral plus corticosteroid started within 72 hours of onset remains evidence-based.

Investigational adjunct for Buerger's disease; absolute tobacco cessation is the only disease-modifying intervention; iloprost and surgical sympathectomy for selected cases.

Investigational adjunct for refractory ischial (ischiogluteal) bursitis; activity modification, hamstring loading, and selective injection remain primary.

Histamine-receptor-acting compound — contributes to local vasodilation at feeding site.